Get the Daily Brief
Latest Biotech News
Guardant and Merck team on liquid‑tissue companion diagnostics for trials
Guardant Health and Merck entered a multi‑year partnership to use Guardant’s liquid and tissue biopsy assays to support enrollment in Merck’s global clinical studies and to co‑develop companion...
GSK agrees $2.2B deal: picks up Rapt’s long‑acting anti‑IgE
GSK agreed to acquire Rapt Therapeutics for $2.2 billion to secure ozureprubart, a long‑acting anti‑IgE monoclonal antibody in Phase IIb development for food allergies. The deal gives GSK rights...
Boston Scientific to buy Penumbra: $14.5B move into thrombectomy
Boston Scientific announced a definitive agreement to acquire Penumbra for $14.5 billion in cash and stock to expand its cardiovascular and neurovascular portfolio. The deal brings Penumbra’s...
Capricor updates BLA after FDA review of HOPE‑3 topline results
Capricor Therapeutics issued a regulatory update on its Biologics License Application for Deramiocel — an investigational cell therapy for Duchenne muscular dystrophy — following FDA review of...
CMS OKs reimbursement for Illumina’s TruSight: $2,989.55 per test
The US Centers for Medicare & Medicaid Services granted reimbursement for Illumina’s TruSight Oncology Comprehensive assay at $2,989.55 per test, effective Jan. 1, 2026. Illumina said the...
Engineered bacteria secrete adhesive therapeutics: Living glue treats IBD in mice
Two complementary Nature Portfolio reports describe engineered nonpathogenic E. coli programmed with a blood‑inducible circuit to secrete a barnacle‑inspired adhesive protein (CP43K) and a...
Engineered UGA suppressor tRNA: Broadens AAV therapeutic reach
A Nature Biotechnology paper described an engineered UGA suppressor tRNA gene intended for disease‑agnostic delivery via AAV vectors. The suppressor tRNA enables readthrough of UGA stop codons in...
Scientists build bacteriophages with AI... Raises biosecurity questions
Researchers reported computational models capable of designing complete bacteriophage genomes from scratch, demonstrating that AI can generate functional viral constructs. The work illustrates...
FDA clears IND: D3 Bio’s KRAS G12D inhibitor moves to clinic
D3 Bio secured FDA IND clearance for D3S‑003, a small‑molecule inhibitor targeting KRAS G12D, enabling a first‑in‑human Phase I study in patients with advanced solid tumors harboring the KRAS G12D...
Parse, Graph team up – Atlas to profile hundreds of millions of immune cells
Parse Biosciences and Graph Therapeutics launched a strategic collaboration to build a large‑scale immune cell perturbation atlas. Graph will generate patient‑derived disease models via its...
Guardant, Merck ink multi‑year deal – Liquid and tissue tests to support trials
Guardant Health and Merck announced a multi‑year partnership to develop and commercialize companion diagnostics using Guardant’s portfolio of liquid and tissue biopsy assays to support patient...
GSK buys Rapt for $2.2B—ozureprubart eyed for 12-week dosing
GSK agreed to acquire Rapt Therapeutics for $2.2 billion to gain global rights to ozureprubart, an anti‑IgE antibody candidate being developed as a less‑frequent dosing alternative for food...
Boston Scientific to acquire Penumbra for $14.5B—cardio and neurovascular scale-up
Boston Scientific announced a $14.5 billion cash-and-stock deal to acquire Penumbra, expanding its portfolio into mechanical thrombectomy, embolization and neurovascular devices. The transaction...
Merck–Moderna vaccine sustains 49% melanoma risk cut at five years
Long‑term follow-up from a trial combining a Merck‑Moderna cancer vaccine candidate with Keytruda shows a sustained 49% reduction in risk of recurrence or death at five years, boosting the...
AstraZeneca pays up to $630M for China rights to AbelZeta CAR‑T
AstraZeneca agreed to pay up to $630 million to acquire the remaining China rights to C‑CAR031 from AbelZeta Pharma, consolidating global control of the GPC3‑targeted armored CAR‑T under...
D3 Bio wins IND clearance for KRAS G12D inhibitor—first‑in‑human trial cleared
D3 Bio secured FDA IND clearance for D3S‑003, a KRAS G12D small‑molecule inhibitor, enabling a first‑in‑human phase I study in patients with advanced solid tumors harboring that mutation. The...
Engineered living glue: bacteria sense bleeding and secrete therapeutics in IBD models
Researchers engineered nonpathogenic E. coli with a blood‑inducible circuit that secretes a barnacle‑derived adhesive protein (CP43K) and the gut‑repair factor TFF3 in response to gastrointestinal...
Engineered suppressor tRNA broadens AAV delivery—disease‑agnostic translation tool
A Nature Biotechnology study reported an engineered UGA suppressor tRNA designed for in vivo use with AAV vectors to restore protein expression across premature stop codons, offering a potentially...
Exciva raises €51M ($59M) Series B to push Alzheimer’s agitation candidate into Phase 2
German biotech Exciva closed a €51 million ($59 million) Series B to advance its lead program for agitation in Alzheimer’s disease into a mid‑stage clinical trial. The funding will support a Phase...
AI designs bacteriophages from scratch—scientists flag biosecurity implications
Researchers used AI models to design complete bacteriophage genomes de novo, demonstrating the ability to generate synthetic phages that can be synthesized and potentially deployed for therapeutic...